Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Karthik Akinapelli"'
Autor:
Pedro Luis Gonzalez, Urania Rappo, Karthik Akinapelli, Jennifer S McGregor, Sailaja Puttagunta, Michael W Dunne
Publikováno v:
Drugs in Context, Vol 7, Pp 1-10 (2018)
Background: Persons who inject drugs (PWID) are at increased risk of acute bacterial skin and skin structure infections (ABSSSIs), a growing healthcare concern. Multiple medical, social, and economic issues, including adherence and comorbidities, com
Externí odkaz:
https://doaj.org/article/3ecc525fb387486db854b4c900db82ae
Autor:
Urania Rappo, H. Bryant Nguyen, Sailaja Puttagunta, Caroline Ojaimi, Karthik Akinapelli, Michael W. Dunne
Publikováno v:
Western Journal of Emergency Medicine, Vol 21, Iss 4 (2020)
Introduction: A small percentage of patients with skin infections later develop necrotizing fasciitis (NF). Diagnostic testing is needed to identify patients with skin infections at low risk of NF who could be discharged from the emergency department
Externí odkaz:
https://doaj.org/article/9814e844815b45a489df8faf85acc98e
Autor:
Michael W Dunne, Steven I Aronin, Anita F Das, Karthik Akinapelli, Jeanne Breen, Michael T Zelasky, Sailaja Puttagunta
Publikováno v:
Clinical Infectious Diseases. 76:78-88
Background Sulopenem is a thiopenem antibiotic being developed for the treatment of multidrug-resistant infections. The availability of both intravenous (IV) and oral formulations will facilitate earlier hospital discharge. Methods Hospitalized adult
Autor:
Michael W Dunne, Steven I Aronin, Anita F Das, Jayanti Gupta, Karthik Akinapelli, Michael T Zelasky, Sailaja Puttagunta, Helen W Boucher
Publikováno v:
Clinical Infectious Diseases.
Autor:
Pedro L. Gonzalez, Urania Rappo, Karthik Akinapelli, Jennifer S. McGregor, Sailaja Puttagunta, Michael W. Dunne
Publikováno v:
Infectious Diseases and Therapy. 11:423-434
Autor:
Michael W Dunne, Steven I Aronin, Anita F Das, Karthik Akinapelli, Michael T Zelasky, Sailaja Puttagunta, Helen W Boucher
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
Background There are limited treatment options for uncomplicated urinary tract infection (uUTI) caused by resistant pathogens. Sulopenem etzadroxil/probenecid (sulopenem) is an oral thiopenem antibiotic active against multidrug-resistant pathogens th
Autor:
Karthik Akinapelli, Michael Nowak, Sailaja Puttagunta, Michael W. Dunne, Jennifer C. Nelson, Jennifer S McGregor, Veronica Mas Casullo, Pedro L Gonzalez, Urania Rappo
Publikováno v:
Infectious Diseases and Therapy
Introduction Dalbavancin is a lipoglycopeptide antibiotic approved as a single- and two-dose regimen for adults with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive organisms. We present nephrotoxicity
Autor:
Patrick Gillard, Sailaja Puttagunta, Karthik Akinapelli, Katelyn R. Keyloun, Pedro L Gonzalez, Urania Rappo, Michael W. Dunne, Yan Liu
Publikováno v:
Journal of Global Antimicrobial Resistance. 17:60-65
Objectives Treatment of acute bacterial skin and skin structure infections (ABSSSIs) in the outpatient setting has potential advantages. We performed a subanalysis of outcomes for patients treated as outpatients versus inpatients with dalbavancin, a
Autor:
Sailaja Puttagunta, Michael W. Dunne, Karthik Akinapelli, Pedro L Gonzalez, Urania Rappo, Jennifer S McGregor
Publikováno v:
Drugs in Context, Vol 7, Pp 1-10 (2018)
Drugs in Context
Drugs in Context
Background Persons who inject drugs (PWID) are at increased risk of acute bacterial skin and skin structure infections (ABSSSIs), a growing healthcare concern. Multiple medical, social, and economic issues, including adherence and comorbidities, comp
Autor:
Michael Zelasky, Michael W. Dunne, Karthik Akinapelli, Anita Das, Helen W. Boucher, Steven Aronin
Publikováno v:
Open Forum Infectious Diseases
Background Sulopenem is a broad-spectrum IV and oral penem antibiotic being developed for the treatment of infections caused by multidrug-resistant bacteria. Overall and Clinical Success in Patients with an Uncomplicated UTI at Test of Cure (TOC) and